Scientists report major breakthrough in age-related macular degeneration prevention

ByConnor Hodde

Scientists at Trinity College Dublin have discovered that a part of the immune system called the inflammasome is involved in regulating the development of one of the most common forms of blindness, called Age-Related Macular Degeneration (AMD). They have discovered that controlling an inflammatory component IL-18, in cases of Age-Related Macular Degeneration (AMD) could prevent the development of the disease.

http://medicalxpress.com/news/2012-04-scientists-major-breakthrough-age-related-macular.html

Similar Posts

A bionic prosthetic eye that speaks the language of your brain

ByConnor Hodde

Sheila Nirenberg of Cornell University has been trying to work out how the retina in your eye communicates with your brain — and judging by a recent talk at TEDMED, it seems like she’s actually cracked it. Nirenberg produced mathematical equations that, with startling accuracy, encode images into neuron pulses that can be understood by an…

Rosemary Compound Shown To Help Fight Macular Degeneration In Mouse Model

ByConnor Hodde

A new study led by the Sanford-Burnham Medical Research Institute reports that carnosic acid, found in the herb rosemary, actually promotes eye health. Led by Dr. Stuart A. Lipton, the team found that carnosic acid protects the retina from degeneration and toxicity in cell culture and in rodent models of light-induced retinal damage. This suggests…

Nerve Injury Appears to be Root of Diabetes-related Vision Loss

ByConnor Hodde

Diabetes-related vision loss most often is blamed on blood vessel damage in and around the retina, but new research indicates that much of that vision loss may result from nerve cell injury that occurs long before any blood vessels are damaged.  After three months on a high-fat diet, the animals had developed obesity-related glucose intolerance,…

Nanotechnology-Based Cancer Treatment Can Reduce Side Effects

ByConnor Hodde

Conventional cancer treatments are accompanied by a host of side effects such as nausea and vomiting. The intensity of the side effects is many a time so acute that it poses a deterrent to further treatment. The reason behind the side effects is that existing cancer treatment methods do not address just the cancerous cells,…

Once-daily CsA-MiDROPS™ are superior to other CsA drops dosed twice-daily

ByConnor Hodde

Ophthalmic distribution studies indicate significantly increased drug concentration with CsA-MiDROPS (Cyclosporine A microemulsion) compared with Restasis. CsA-MiDROPS is well tolerated with little toxicity in a 2-week tolerability study. In the DED model, both 0.05% and 0.1% CsA-MiDROPS conferred a significant effect and were more effective than Restasis for treating experimental DED when dosed twice per…

Mayo Clinic work shows possible Lucentis side effect

ByConnor Hodde

At the Amercian Academy of Opthalmology 115th Annual Meeting, findings were presented from a retrospective study conducted after a Mayo Clinic opthalmologist noticed an increase in intraoccular pressure (IOP) in her patients using Genentech’ (Roche) Lucentis (ranibizumab), an FDA-approved drug for the treatment of age-related macular degeneration (AMD). MARINA (Minimally Classic/OccultTrial of the Anti-Vascular Endothelial…